SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-108892
Filing Date
2023-10-13
Accepted
2023-10-12 19:39:37
Documents
13
Period of Report
2023-10-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2328385d1_8k.htm   iXBRL 8-K 27026
2 EXHIBIT 99.1 tm2328385d1_ex99-1.htm EX-99.1 15748
  Complete submission text file 0001104659-23-108892.txt   222692

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20231010.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20231010_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20231010_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2328385d1_8k_htm.xml XML 3405
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 231323638
SIC: 2834 Pharmaceutical Preparations